Purchase this article with an account.
Ermete Giancipoli, Giuseppe D'Amico Ricci, Tiziana Porcu, Ciriaco Carru, Francesco Boscia, Antonio Pinna; Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency and age-related macular degeneration in a Sardinian male population, Italy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):355.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The reported prevalence of G6PD deficiency in Sardinia, Italy, ranges from 8% to 15%. Hemizygous males have totally deficient erythrocytes. Evidence indicates that patients with G6PD deficiency are protected against ischemic heart and cerebrovascular disease, retinal vein occlusion, and nonarteritic anterior ischemic optic neuropathy. The purpose of this study was to assess the prevalence of G6PD deficiency in Sardinian men with age-related macular degeneration (AMD) and ascertain whether G6PD deficiency may have a protective effect against AMD.
G6PD blood levels were measured in 79 men with AMD. 79 age-matched men without AMD undergoing cataract surgery served as controls. The Z test was used to assess differences in G6PD deficiency prevalence rates between groups. The odds ratio (OR) was used to evaluate the association between G6PD deficiency and AMD.
G6PD deficiency was found in 7 (8.9%) out of 79 patients with AMD (mean age: 78±7.2 years) and in 8 (10.1%) out of 79 controls (mean age 78±7 years). Differences between AMD patients and controls were not statistically significant (Z-score: -0.23, P: 0.8). G6PD deficiency showed no association with AMD (OR: 0.86; 95% Confidence Interval: 0.3-2.5; P: 0.79).
Results suggest that G6PD deficiency has no protective effect against AMD nor is a risk factor for this degenerative macular disorder.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only